AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), sold 1,238 shares of the company.
On April 29, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), sold 4,084 shares of the company.